PureCycle Technologies, Inc. (PCT) · Nov 4, 2026 · Earnings
Miss — Revenue $2.3M vs ~$8.28M consensus
PureCycle earnings show customer progress and lower operating spend, but revenue missed sharply as New Jersey delays pushed major food-contact programs into 2027.
PureCycle is in the commercial-ramp phase at its Ironton recycling plant, converting qualified recycled-polypropylene programs into recurring shipments while funding its next growth project in Thailand. Its prior quarter had shown first P&G commercial deliveries, on-site compounding, and $4.5 million of revenue, so the central question was whether that early pipeline would translate into a much larger Q3 ramp.
The quarter missed the ramp that consensus was expecting. Revenue fell to $2.3 million from $4.5 million in Q2 and $2.4 million a year earlier, versus published consensus of approximately $8.28 million. The company directly attributed the shortfall to Ironton operating issues and New Jersey delays, making this more than a normal timing variance.
| Q3 2026 | Q2 2026 | Q3 2025 | Consensus | |
|---|---|---|---|---|
| Revenue ($MM) (Financial Results) | $2.3 | $4.5 | $2.4 | $8.28 |
| PureFive production (MM lbs) (Key Performance Indicators) | 5.2 | 4.5 | 7.3 | |
| Monthly operations spending ($MM) (Finance) | $7.8 | $8.4 | $8.3 | $8.0–$9.0 guide |
| Adjusted EBITDA ($MM) (Financial Results) | $(28.0) | $(28.6) | ||
| Total liquidity ($MM) (Cash and Liquidity) | $193.0 | $236.9 |
The commercial story is progressing, but the timing has slipped materially. P&G products are now on shelves, hot-lid shipments began in October, and additional cosmetics and personal-care programs are moving toward shipments or final qualification. However, the New Jersey exemption extension pushed roughly 15 food-contact programs—about 50 million pounds of eventual annual volume—out of the expected 2026 launch window and, in many cases, beyond 2027. 〔0〕
Operations improved sequentially, but not enough to prove a broad ramp. Ironton produced 5.2 million pounds of PureFive resin, up 14% from Q2, and management says the operational problems were resolved. 〔1〕 Still, production remained well below Q3 2025, while management now says output is being matched to current commercial demand rather than running ahead of confirmed shipments. That reduces near-term execution risk but also signals that utilization will rise only as delayed programs actually convert.
The balance sheet and cost actions buy time, not proof of profitability. Monthly operating spending came in below the prior $8.0–$9.0 million guide, and the company is adding further cost reductions through early 2027. Total liquidity was $193 million plus an undrawn $200 million revolver, while the facility maturity now extends to September 2028. That supports continued execution, but project spending is now expected to finish around $51 million for 2026—above the prior $45–$50 million range—and Thailand financing remains unfinished.
The executive-chairman change adds operating experience but does not change the near-term scorecard. Fernando Musa brings polypropylene production and brand-selling experience, which is relevant to the Ironton ramp, while Dustin Olson remains CEO. 〔2〕 It is a support measure around execution rather than evidence that the commercial model has already reached scale.
Bottom line: PureCycle is showing real customer adoption, but the quarter says the commercial ramp is arriving later and more unevenly than expected. The story remains intact, yet the revenue miss and New Jersey-driven delay make this a meaningful setback rather than confirmation of the planned acceleration.
Q4 results and 2027 project-spend range
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!